4-[(2R)-5-chloro-2-(4,5,6,7-tetrahydro-2,1-benzoxazol-3-yl)-2,3-dihydro-1-benzofuran-7-yl]quinoline-7-carbonitrile
C25H18ClN3O2 — CID 160666048
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[(2R)-5-chloro-2-(4,5,6,7-tetrahydro-2,1-benzoxazol-3-yl)-2,3-dihydro-1-benzofuran-7-yl]quinoline-7-carbonitrile
4-[(2R)-5-chloro-2-(4,5,6,7-tetrahydro-2,1-benzoxazol-3-yl)-2,3-dihydro-1-benzofuran-7-yl]quinoline-7-carbonitrile (PubChem CID 160666048) has the molecular formula C25H18ClN3O2 and a molecular weight of 427.89 g/mol. Its IUPAC name is 4-[(2R)-5-chloro-2-(4,5,6,7-tetrahydro-2,1-benzoxazol-3-yl)-2,3-dihydro-1-benzofuran-7-yl]quinoline-7-carbonitrile.
Molecular Properties
| Compound Name | 4-[(2R)-5-chloro-2-(4,5,6,7-tetrahydro-2,1-benzoxazol-3-yl)-2,3-dihydro-1-benzofuran-7-yl]quinoline-7-carbonitrile |
|---|---|
| PubChem CID | 160666048 |
| Molecular Formula | C25H18ClN3O2 |
| Molecular Weight | 427.89 g/mol |
| Exact Mass | 427.11 |
| IUPAC Name | 4-[(2R)-5-chloro-2-(4,5,6,7-tetrahydro-2,1-benzoxazol-3-yl)-2,3-dihydro-1-benzofuran-7-yl]quinoline-7-carbonitrile |
| SMILES | N#Cc1ccc2c(-c3cc(Cl)cc4c3O[C@@H](c3onc5c3CCCC5)C4)ccnc2c1 |
| InChI | InChI=1S/C25H18ClN3O2/c26-16-10-15-11-23(25-19-3-1-2-4-21(19)29-31-25)30-24(15)20(12-16)17-7-8-28-22-9-14(13-27)5-6-18(17)22/h5-10,12,23H,1-4,11H2/t23-/m1/s1 |
| InChIKey | RMHURKFYLDHPQC-HSZRJFAPSA-N |
| XLogP | 5.97 |
| TPSA | 71.94 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 427.89 |
| LogP ≤ 5 | 5.97 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 160666048 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.